Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Safety and Efficacy of pALG in Conditioning Regimen for HLA-Matched Sibling HSCT in Patients With SAA or Hematological Malignancies ( pALG-MSDHSCT )

Safety and Efficacy of Anti-human T-cell Porcine Immunoglobulin in Conditioning Regimens for HLA Sibling Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Severe Aplastic Anemia (SAA)/Hematological Malignancies

This study is a single-arm clinical study designed to evaluate the safety and efficacy of p-ALG in HLA sibling identical Hematopoietic stem cell transplantation( HSCT) conditioning regimens for severe aplastic anemia (SAA)/hematologic malignancies in patients diagnosed with hematologic malignancies or sSAA requiring allogeneic HSCT from our center. Graft anti-host disease (GVHD) is the most common and severe complication of allogeneic HSCT, which significantly affects survival and quality of life. Even among recipients of HLA-identical sibling HSCT (MSD-HSCT), the incidence of acute GVHD( aGVHD) and chronic GVHD (cGVHD) reaches 40-50% and 30-70%, respectively.

Studieoversikt

Detaljert beskrivelse

This study was designed to explore the safety and efficacy of anti-human T cell porcine immunoglobulin p-ALG in the conditioning regimen of HLA sibling allogeneic hematopoietic stem cell transplantation for severe aplastic anemia (SAA)/hematological malignancies in 60 patients.

(1)30 patients with severe aplastic anemia type I and type II underwent MSD-HSCT, p-ALG: 20mg/kg/d for 5 days; (2)30 patients with malignant hematologic diseases, aged over 40 years, either as patients or donors, underwent sibling allogeneic transplantation, with pALG administered at 20mg/kg/d for 3 days.

The enrollment time was 24 months, and patients were followed up for 24 months to evaluate long-term efficacy.

Pharmacokinetics, inflammatory cytokines and active antibodies were measured on day 0 before pALG administration and on days 3, 5, 7, 14, 21, 28 and 60 after p-ALG administration.

Routine follow-up after transplantation was performed to assess implantation and chimerism rate, immune reconstitution, infection prevention, graft versus host disease prevention, treatment-related mortality, and overall survival.

Blood routine, urine routine, liver and kidney function, clinical manifestations and ECOG score were recorded on 28± 7,60 ± 7,90 ± 7,180 ± 7,270 ± 7,360 ± 7,450 ± 7,540 ± 7,630 ± 7,720 ±7 days after transplantation; implantation rate, OS, aGVHD, cGVHD, CMV, EB virus and other infections were recorded.

Studietype

Observasjonsmessig

Registrering (Antatt)

60

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, Kina, 300020
        • National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College Hospital

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Barn
  • Voksen
  • Eldre voksen

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

Patients with severe aplastic anemia (type I/II) or hematologic malignancies undergoing HLA-matched sibling hematopoietic stem cell transplantation.

Beskrivelse

Inclusion Criteria

  1. age: no age limit for severe aplastic anemia type I or II, patient or donor age>40 years for hematologic malignancies;
  2. gender: no gender limit;
  3. sibling identical hematopoietic stem cell transplantation;
  4. fair general status, ECOG score <2 points;
  5. no age limit for severe aplastic anemia, no gender limit; patient or donor age>40 years for hematologic malignancies.

Exclusion Criteria:

  1. uncontrolled viral, bacterial and fungal infections (disease progression during antifungal therapy);
  2. pregnant and lactating patients or patients unable to use appropriate contraception during treatment;
  3. psychiatric disorders or other medical conditions unable to comply with study treatment and monitoring requirements;
  4. known seropositive for HIV, active hepatitis B, active hepatitis C virus, or syphilis;
  5. history of tumor and treatment for any tumor within the past 3 years;
  6. Prior hematopoietic stem cell transplantation;
  7. Active heart disease, defined as one or more of the following: ① Long QTc syndrome or QTc interval>480ms;② Complete left bundle branch block, degree II or III atrioventricular block;③ History of arrhythmia requiring medication or severe clinical symptoms;④ American New York Heart Association classification ≥II; ④ Left ventricular ejection fraction less than 50%; History of myocardial infarction, unstable angina pectoris, severe unstable ventricular arrhythmia or any other arrhythmia requiring treatment, history of clinically serious pericardial disease, or ECG evidence of acute ischemic or active conduction system abnormalities within 6 months prior to enrollment.
  8. Subjects considered unsuitable for enrollment by the investigator.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Observasjonsmodeller: COHORT
  • Tidsperspektiver: PROSPECTIVE

Kohorter og intervensjoner

Gruppe / Kohort
Intervensjon / Behandling
p-ALG cohort

(1)30 patients with severe aplastic anemia type I and type II underwent MSD-HSCT, p-ALG: 20mg/kg/d for 5 days; (2)30 patients with malignant hematologic diseases, aged over 40 years, either as patients or donors, underwent sibling allogeneic transplantation, with pALG administered at 20mg/kg/d for 3 days.

(1)30 patients with severe aplastic anemia type I and type II underwent MSD-HSCT, p-ALG: 20mg/kg/d for 5 days; (2)30 patients with malignant hematologic diseases, aged over 40 years, either as patients or donors, underwent sibling allogeneic transplantation, with pALG administered at 20mg/kg/d for 3 days.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Incidence of acute graft-versus-host disease (aGVHD)
Tidsramme: within 100 days after hematopoietic stem cell infusion

aGVHD was evaluated via the modified Glucksberg criteriahematopoietic stem cell transplantation, diagnosed and graded according to standard criteria.

within 100 days after hematopoietic stem cell infusion
Incidence of chronic graft-versus-host disease (cGVHD)
Tidsramme: 5 years after hematopoietic stem cell transplantation

cGVHD was defined in accordance with the National Institutes of Health (NIH) guidelines

5 years after hematopoietic stem cell transplantation

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
1-year implantation rate
Tidsramme: 1-year

The rate of primary and secondary poor engraftment of neutrophils and platelets within 1 year

1-year
Overall survival rate
Tidsramme: 5 years after hematopoietic stem cell transplantation

All-cause mortality from hematopoietic stem cell infusion to the last follow-up

5 years after hematopoietic stem cell transplantation
Rejection (AA) or recurrence (malignant)
Tidsramme: 5 years after hematopoietic stem cell transplantation

Rejection (AA) or recurrence (malignant) from hematopoietic stem cell infusion to the last follow-up

5 years after hematopoietic stem cell transplantation
Incidence of fungal infection
Tidsramme: 2 years after hematopoietic stem cell infusion

Incidence of fungal infection from hematopoietic stem cell infusion to the last follow-up

2 years after hematopoietic stem cell infusion
Incidence of cytomegalovirus infection
Tidsramme: 2 years after hematopoietic stem cell infusion

Incidence of cytomegalovirus infection from hematopoietic stem cell infusion to the last follow-up

2 years after hematopoietic stem cell infusion
Incidence of Epstein-Barr virus infection
Tidsramme: 2 years after hematopoietic stem cell infusion

Incidence of Epstein-Barr virus infection from hematopoietic stem cell infusion to the last follow-up

2 years after hematopoietic stem cell infusion
Transplant-related mortality
Tidsramme: 5 years after hematopoietic stem cell infusion

Non-relapse/progression-related death occurring within 100 days after hematopoietic stem cell infusion

5 years after hematopoietic stem cell infusion
Drug-related toxic and side effects from hematopoietic stem cell infusion to the last
Tidsramme: 2 years after hematopoietic stem cell infusion

Drug-related toxic and side effects from hematopoietic stem cell infusion to the last follow-up

2 years after hematopoietic stem cell infusion

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

30. november 2026

Primær fullføring (Antatt)

31. august 2028

Studiet fullført (Antatt)

31. august 2028

Datoer for studieregistrering

Først innsendt

2. november 2026

Først innsendt som oppfylte QC-kriteriene

11. november 2026

Først lagt ut (Faktiske)

17. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

17. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

11. november 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere